Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04622007 · ClinicalTrials.gov registry record · Phase 2
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Effector Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 20
- Study locations
NCT04622007: Active Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Effector Therapeutics.
NCT04622007 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Effector Therapeutics. The registered enrollment target is 68 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04622007, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Effector Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 20
- Study locations
Study Summary
Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Pemetrexed
- DRUG Tomivosertib
Study Locations (20)
Arizona
- Arizona Oncology Associates, PC - HAL (W Bell Rd) - Glendale
- Arizona Oncology Associates, PC - NAHOA (W. McDowell) - Goodyear
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC-NAHOA (N. Windsong) - Prescott Valley
- Arizona Oncology Associates (N. Pima Rd) - Scottsdale
- Arizona Oncology Associates, PC - HAL - Scottsdale
- Arizona Oncology Associates, PC - HAL - Tempe
- Arizona Oncology Associates, PC - HOPE (W. Orange Grove) - Tucson
- Arizona Oncology Associates, PC - HOPE (W. Rudasill Rd) - Tucson
- Arizona Oncology Associates, PC - HOPE - Tucson
- Arizona Oncology Associates, PC - HOPE (West St.) - Tucson
California
- University of California, Los Angeles (UCLA) - Alhambra - Alhambra
- Comprehensive Blood And Cancer Center - Bakersfield
- TOI Clincal Research - Cerritos
- California Cancer Associates for Research & Excellence (San Diego Pacific Oncology and Hematology Associates) - Encinitas - Encinitas
- City of Hope - Long Beach Elm - Long Beach
Alabama
- Southern Cancer Center - Daphne
- Southern Cancer Center, PC (Mobile Infirmary Circle) - Mobile
- Southern Cancer Center, PC (Airport Blvd) - Mobile
- Southern Cancer Center, PC (Dauphin St) - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2024-12-09 |
| Phase | Phase 2 |
What the registry record for NCT04622007 still lists
NCT04622007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04622007 names 20 study sites across 3 states, led by Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04622007 about?
NCT04622007 is a clinical study titled "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)". Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
What is the current status of trial NCT04622007?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2021-06-02. Estimated completion is 2024-12-09.
What conditions does trial NCT04622007 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04622007?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Pemetrexed (DRUG), Tomivosertib (DRUG).
Who is sponsoring clinical trial NCT04622007?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04622007 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04622007's enrollment target sits among peer trials
68 296th of 454 higher than 158 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI